Hokkaido University and BostonGene are using their AI-powered genome profiling platform to advance precision cancer treatment.
Tuesday, May 12, 2026
BostonGene, a developer of AI for cancer and immunology, today announced a research partnership with Hokkaido University. This multi-year initiative aims to support the advancement of precision medicine, improve treatment outcomes for Japanese patients, and generate actionable, high-quality, and clinically useful data.
BostonGene leverages next-generation sequencing and its proprietary AI-powered platform to perform integrated analyses of DNA, RNA, and immune system profiling. It analyzes genomic and immune profiles of tumor samples from over 20 cancer types provided by Hokkaido University. These analyses can provide valuable information for identifying patient-specific disease drivers and influencing treatment decisions.
"BostonGene's AI-powered platform provides the advanced analytical information necessary to translate clinical data into actionable insights," said Dr. Ichiro Kinoshita, research leader at Hokkaido University, professor of cancer gene diagnosis, and head of the Department of Medical Oncology, and Dr. Yutaka Hatanaka, specially appointed associate professor at the Advanced Diagnostic Technology Development Center, Institute for Medical and Health Science Research and Development, Hokkaido University Hospital. "By providing our scientific expertise and patient samples, we will promote more personalized and effective approaches for cancer patients in Japan."
"This partnership could serve as a good example of how complex patient data can be leveraged through BostonGene's AI-powered analysis to advance clinical treatment," said Yukimasa Shiotsu, President and CEO of BostonGene Japan. "This partnership strengthens our commitment to advancing translational oncology, which has a high clinical need."
About BostonGene:
BostonGene leverages AI-powered models in oncology and immunobiology to deliver disease-level insights, enabling precise decision-making for oncological and immunological diseases from drug discovery to clinical practice. By integrating multimodal data including genomics, transcriptomes, immunology, and clinical signals, BostonGene generates bio-evidence-based intelligence to optimize patient selection, trial design, and therapeutic strategies. This provides scalable AI-driven decision-making that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical companies and academic institutions to accelerate the delivery of precision therapies and continuously expand its capabilities to address emerging diseases and complex biological systems. For more information, please visit www.BostonGene.com
About BostonGene Japan:
BostonGene Japan Co., Ltd. is a joint venture established in Tokyo by BostonGene, NEC, and Japan Industrial Partners, aiming to promote personalized medicine and dramatically improve patient outcomes. The company will leverage BostonGene's AI-powered platform to accelerate drug development and personalize cancer treatment to suit individual patients.
Contacts
Media:
BostonGene
Erin Keleher
+1-617-283-2285
Erin.Keleher@BostonGene.com
Source: businesswire.com
